HK Stock MarketDetailed Quotes


  • 4.710
  • -0.140-2.89%
Market Closed Jul 19 16:08 CST
412.78MMarket Cap-671P/E (TTM)

About SIRNAOMICS-B Company

sirNomics is the first and only clinical-stage RNA therapy biopharmaceutical company with significant market positions in both China and the US. Through exploration and development of innovative drugs, they are used in human diseases with significant unmet medical needs. The clinical development pipeline focuses on oncology and fibrosis indications. Our management team shares extensive experience and ability to explore, develop, and commercialize RNAi therapies. Our mission is to be a fully integrated international biopharmaceutical company that relies on our deep experience in RNA therapy and novel delivery platform technology to rapidly discover, develop and (if approved) commercialize a range of transformative therapies and vaccines for patients suffering from a variety of rare and marketable diseases.

Company Profile

Listing DateDec 30, 2021
Issue Price65.90
Shares Offered7.54M share(s)
FoundedOct 15, 2020
Registered AddressCayman Islands
Chairmanyang lu
Secretarytingzhang liang
Audit InstitutionDeloitte & Touche Tohmatsu Certified Public Accountants
Company CategoryOther
Registered OfficePO Box 309, Ugland House Grand Cayman, KY1-1104 Cayman Islands
Head Office and Principal Place of Business46th floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong
Fiscal Year Ends12-31
MarketHong Kong motherboard
Business Sirnaomics Ltd is an investment holding company. The company and its subsidiaries are clinical-stage biotechnology companies that develop and commercialize ribonucleic acid interference (RNAi) technology and multiple therapies. The company is dedicated to the discovery and development of medicines for the region's unmet medical needs. Its main clinical candidates include STP705 and STP707. Its STP705 is a sterile pharmaceutical product used to treat non-melanoma skin cancer (NMSC), including squamous cell carcinoma in situ and basal cell carcinoma (BCC), keloids that recur after keloid resection, hypertrophic scars (HTS), and solid liver tumors, as well as for medical aesthetics. Its STP707 is a sterile pharmaceutical product used to treat solid tumors, including liver cancer, metastatic squamous cell skin cancer (CsCC), and non-small cell lung cancer. It is utilizing its dual delivery platform, which includes polypeptide nanoparticles (PNP) and GalAhead.

Company Executives

  • Name
  • Position
  • Salary
  • yang lu
  • Chairman of the Board,CEOs,President,Executive Director,Nomination Committee Members,Authorized Representative
  • --
  • David Mark Evans
  • Head of Drug Development and Collaboration
  • --
  • xiaochang dai
  • Executive Director,Remuneration Committee Members
  • --
  • mincong huang
  • Non-executive directors,Audit Committee Members
  • --
  • jiankang zhang
  • Non-executive directors
  • --
  • changhai yu
  • Independent Non-Executive Director,Chairman of the Nomination Committee,Remuneration Committee Members
  • --
  • mengying huang
  • Independent Non-Executive Director,Remuneration Committee Chairman,Audit Committee Members
  • --
  • muxian sheng
  • Independent Non-Executive Director,Chairman of the Audit Committee,Nomination Committee Members
  • --
  • yun zhang
  • China Chief Financial Officer,Board Secretary
  • --
  • yongji ye
  • Vice President of Corporate Finance
  • --
  • yongxiang wang
  • Chief Manufacturing Officer
  • --
  • tingzhang liang
  • Authorized Representative,Company Secretary
  • --


Analyst Rating

No Data

Price Target

No Data

Heat List
Latest Price